Tuesday, August 9, 2022
  • About Us
  • ImagiNATION
  • Rate Card
  • Contact Us
The Nation Online
Advertisement
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Life & Style
    • Every Woman
      • Soul
      • Family
    • Religion
    • Feature
  • Society
  • Columns
  • Sports
  • Chichewa
  • Enation
No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Life & Style
    • Every Woman
      • Soul
      • Family
    • Religion
    • Feature
  • Society
  • Columns
  • Sports
  • Chichewa
  • Enation
No Result
View All Result
No Result
View All Result
Home Columns In pursuit of development

Making medicines available and affordable

by Dan Banik
12/09/2019
in In pursuit of development
3 min read
0
Share on FacebookShare on TwitterShare on WhatsAppShare on LinkedinLinkedinShare via Email

Access to, and the affordability of, medicines is now attracting increased global attention. There are several issues at stake – the actual costs of the research and development process, production costs, pricing policies and the bargaining power of individual countries to negotiate good deals.

The rising cost of medicines is the primary complaint of most African countries as they struggle with meagre health budgets. There are many reasons for skyrocketing prices.

Pharmaceutical companies invest a considerable amount of resources in research and development, taking huge financial risks to come up with innovative medical breakthroughs, which are not inexpensive. These companies expect to be compensated for their investments and efforts.

The question is whether such companies are willing to, at some point, forgo huge profits with the goal of making medicines accessible to large parts of the world’s poor. Then there is the matter of manufacturing capacity.

With very few major pharma industries based on the continent, the production capacity in Africa is particularly weak. Indeed, according to some estimates, less than two percent of the medicines consumed in Africa is produced on the continent. The lack of adequate storage and transportation facilities further complicates the problem.

Countries differ in how they regulate drug policy. While the United States pursues a hand-off approach, others such as India try to regulate the sector as much as possible in order to ensure generic competition.

As most patients in India pay out-of-pocket for medicines rather than via insurance policies, the government places strict controls on drug prices while simultaneously allowing local companies to develop generic versions of branded drugs aimed for the domestic market.

The result is that India has branded itself as the pharma to the world, and the African market for India’s generic products is rapidly growing.

In addition to implementing policies that encourage local production, African governments are being encouraged to roll out health insurance schemes that cover the poorest of the poor.

However, such suggestions are easier said than done. Many of the largest pharmaceutical companies are not enthusiastic about providing technical support for local production, arguing that the rise of generic medicines would violate their patents.

And many African governments argue that their limited health budgets do not allow for the introduction of ambitious health insurance programmes.

One issue that experts believe can be more realistically implemented relates to pricing of medicines. The entire negotiation process between pharmaceuticals, insurers and governments is often confidential and it is not always clear who gets a discount on listed prices, and just how big such discounts are.

Apart from greater transparency in pricing, some believe that African countries ought to form coalitions in order to strengthen their procurement processes and bargaining power.

Previous Post

Some budget provisions need rethink

Next Post

MCTU speak on wage hike

Related Posts

In pursuit of development

The future of aid

March 4, 2021
In pursuit of development

The Chinese approach to network-building

February 25, 2021
FILE PHOTO: Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed AstraZeneca logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
In pursuit of development

The ethics of vaccine distribution

February 17, 2021
Next Post

MCTU speak on wage hike

Opinions and Columns

My Turn

Bitcoin and regulations

August 8, 2022
Editor's Note

My beautiful experience as an intern

August 7, 2022
Editor's Note

My beautiful experience as an intern

August 7, 2022
Big Man Wamkulu

What is he up to? He doesn’t drink

August 7, 2022

Malawi-Music.com Top10

Trending Stories

  • Macra ordered MultiChoice Malawi not to 
implement the new proposed tariffs

    Court rebuffs MultiChoice Malawi on new tariffs

    0 shares
    Share 0 Tweet 0
  • Treasury Secretary says won’t resign

    0 shares
    Share 0 Tweet 0
  • Judiciary under probe 

    0 shares
    Share 0 Tweet 0
  • Chakwera’s austerity measures questioned

    0 shares
    Share 0 Tweet 0
  • Nankhumwa rally irks DPP governor

    0 shares
    Share 0 Tweet 0

  • Values
  • Our Philosophy
  • Editorial policy
  • Advertising Policy
  • Code of Conduct
  • Plagiarism disclaimer
  • Disclaimer
  • Privacy Policy
  • Terms of use

© 2022 Nation Publications Limited. All Rights Reserved.

No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Life & Style
    • Every Woman
      • Soul
      • Family
    • Religion
    • Feature
  • Society
  • Columns
  • Sports
  • Chichewa
  • Enation

© 2020 Nation Publications Limited. All Rights Reserved.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.